PT Phapros, Tbk Reports Earnings Results for the Half Year Ended June 30, 2022
July 29, 2022
Share
PT Phapros, Tbk reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was IDR 565,507.08 million compared to IDR 466,238.28 million a year ago. Net income was IDR 11,138.22 million compared to IDR 10,421.98 million a year ago. Basic earnings per share from continuing operations was IDR 13 compared to IDR 12 a year ago.
PT Phapros Tbk is an Indonesia-based pharmaceutical company. The Company's business pillars consist of branded/ethical prescription medicines: hospitals and pharmacies in addition to other healthcare institutions; over-the-counter drugs: pharmacies, retail; generic prescription drugs: government institutions and hospitals; toll-in manufacturing, and medical device. It offers medicines for cardiovascular and hematopoietic, gastrointestinal and hepatobiliary, hormone Genito, urinary endocrine and metabolic, vitamins and minerals nutrition, dermatology, local anesthesia, immune & allergy, and others. The Company's medical devices include ACS MB system, ACS FB and FB PS, Primary Hip Stem, INASHUNT Semilunar Flushing, BoneFill Ortho and NPC-STRIP G. Its branded drugs include Colkatriol 0.25 mcg 30 Cap, Diafac XR, Diafac 500 mg 10 tablets, Spirolactone 25 & 1, Dextamine Syrup 60 ml, Diapros Tablet, Proinfarction, anemone, Pladel, and others. The Company also operates calibration laboratory.
PT PHAPROS TBK 
